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The identification of vascular alterations at the sub-clinical, asymptomatic stages are potentially useful for screening,
prevention and improvement of cardiovascular risk stratification beyond classical risk factors.
Increased intima-media thickness of the common carotid artery is a well-known marker of early atherosclerosis, which
significantly correlates with the development of cardiovascular diseases. More recently, other vascular parameters
evaluating both structural and functional arterial proprieties of peripheral arteries have been introduced, for
cardiovascular risk stratification and as surrogate endpoints in clinical trials. Increased arterial stiffness, which can be
detected by applanation tonometry as carotid-femoral pulse wave velocity, has been shown to predict future
cardiovascular events and to significantly improve risk stratification.
Finally, earlier vascular abnormalities such as endothelial dysfunction in the peripheral arteries, detected as reduced
flow-mediated dilation of the brachial artery, are useful in the research setting and as surrogate endpoints in clinical
trials and have also been suggested for their possible clinical use in the future.
This manuscript will briefly review clinical evidence supporting the use of these different vascular markers for
cardiovascular risk stratification, focusing on the correct methodology, which is a crucial issue to address in order to
promote their use in future for routine clinical practice.
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Cardiovascular (CV) disease is the main cause of mortality
and morbidity worldwide [1]. It has been suggested that
risk estimation by classical risk factors (blood pressure,
glucose, cholesterol) and circulating biomarkers may fail
to adequately predict the risk of CV events because their
fluctuations over time represent many transient and par-
tial “snapshots” rather than a reliable picture of a complex
situation developing over decades [2]. Conversely, imaging
biomarkers of vascular damage might integrate the long-
lasting cumulative effects of all traditional and non-
identified CV risk factors and can be detected as target
organ damage before clinical events occur, at a stage when
interventions may be effective. For that reason, some of
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unless otherwise stated.scientific societies for the improvement of CV risk stratifi-
cation [3,4].
Recently, the concept of early vascular aging was intro-
duced to describe structural and functional changes
occurring in the large arteries with aging, which are accel-
erated in individuals at increased CV risk [5]. It can be
measured by non-invasive techniques, and includes diffuse
intimal thickening, usually measured as carotid intima-
media thickness (C-IMT) [6], aortic stiffening, evaluated
as carotid -femoral pulse wave velocity (cfPWV) [7], and
endothelial dysfunction, commonly measured as brachial
artery flow-mediated dilatation (FMD) [8,9].
Increased C-IMT is an intermediate stage in the con-
tinuum of atherosclerosis, which significantly correlates
with coronary and cerebrovascular disease [10,11]. Other
vascular parameters evaluating structural and functional
arterial proprieties of peripheral arteries were then intro-
duced. Increased cfPWV is already considered a subclin-
ical target organ in hypertensive patients [4], since it has
been shown to predict future cardiovascular events [12]td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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[13]. Earlier vascular abnormalities, such as impaired
FMD [8,9], have also been suggested for their potential
use for risk prediction.
This review will focus on how to proceed to obtain ac-
curate and reliable assessment of these vascular markers,
improving their predictive value for the future use in clin-
ical practice.
Carotid intima-media thickness
C-IMT is measured by high resolution B-mode ultrasound
of extra-cranial carotid arteries and it is the most widely
accepted non-invasive marker of subclinical atheroscler-
osis [6,14]. C-IMT is considered an intermediate pheno-
type of atherosclerosis suitable for use in large-scale
population studies [15], since its increase has been associ-
ated with higher cardiovascular risk [16,17] and with the
presence of advanced stage of atherosclerosis in periph-
eral, cerebral and coronary arteries [18,19]. Epidemio-
logical studies consistently reported a predictive value of
increased C-IMT for myocardial infarction and stroke, in-
dependent of traditional CV factors [10,20-25], which has
been confirmed in a meta-analysis of 12 relevant general
population-based studies [26]. For these reasons, C-IMT
is included in the in European Society of Hypertension
guidelines as target organ damage (class II, level B) in
hypertensive patients [4]. However, based on the results of
a single study, the MESA [27], C-IMT is no longer recom-
mended in the 2013 ACC/AHA Guideline on the assess-
ment of Cardiovascular Risk [28].
C-IMT detected by high-resolution ultrasound repre-
sents the combined width of the intima and media, which
are technically indistinguishable. C-IMT in healthy sub-
jects consists almost entirely of media, with a progressive
intimal thickening or medial hypertrophy determined by
age, gender and hypertension, which do not necessarily re-
flect the atherosclerotic process [29].
The carotid artery is classified into three segments
when undergoing ultrasound study, each approximately
1 cm in length. The most proximal segment, the com-
mon carotid (CCA) represent the 1-cm straight segment
prior identified by a divergence of the near and far walls
as the artery begins to divide into its internal and exter-
nal branches. This focal widening of bifurcation extends
over approximately 1 cm and is labeled the carotid bulb
(CB). The tip of the flow divider separating the diverging
internal carotid artery (ICA) and external carotid artery
defines its distal margin; the final segment is the prox-
imal 1 cm of the ICA. The CCA far wall is the easiest
segment to be examined and the most commonly used
measurement in clinical studies, resulting in a better
prediction of stroke than myocardial infarction [11,30].
Several studies suggest the CCA far wall as the best lo-
cation in terms of feasibility and reproducibility of C-IMT measure [31,32]. Nevertheless, it has been also sug-
gested C-IMT measurements at multiple angles of both
the near and far walls might provide the best balance
between reproducibility, rate of C-IMT progression,
treatment effect and their associated precision in this
low-risk population with subclinical atherosclerosis [33].
Despite it has been proposed that a slower progression
of C-IMT might be associated with a reduction in CV
events [34], a meta-analysis including 41 trials with 18,307
participants showed no significant relationship between
C-IMT regression and events, suggesting that regression
or slowed progression of C-IMT, induced by CV drug
therapies, may not reflect a reduction in CV events [35].
However, it has to be acknowledged that the estimation of
C-IMT in the vast majority of the studies was obtained
manually by calipers, without the use of an automatic ap-
proach for the measurement. Therefore, accuracy of C-
IMT and, particularly, of its changes over time is not
simply a methodological question but might have import-
ant consequences in the clinical setting. B-mode image
processing-based devices (Figure 1) and radio-frequency
(RF)-based echo-tracking systems are now widely available
and should definitely be adopted to increase precision and
accuracy. RF-based devices are considered very accurate
since they are based on signals with higher spatial
resolution than B-mode data [36,37]. However, robust
image-based systems have been recently validated, show-
ing similar reproducibility [38,39]. These systems require
high quality of the scans and standardized system settings
(e.g. dynamic range, depth gain set or filtering) [40], that
should clearly reported, especially for follow-up studies
[41]. The reliability of B-mode based systems has been re-
cently acknowledged by the scientific community, since
measures obtained by this technique were used for the
definition of C-IMT reference values obtained by echo-
tracking [42]. C-IMT reference values were obtained by
echo-tracking in a cohort of 24871 individuals from 24
research centers worldwide [42], and allowed estimation
of C-IMT age- and sex-specific percentiles in a healthy
population of the 4234 individuals without CV disease,
CV risk factors, and blood pressure-, lipid-, and/or
glucose-lowering medication. These reference values will
favor the use of C-IMT assessment in clinical practice,
possibly for a better risk classification particularly con-
cerning C-IMT modifications over time.
Pulse wave velocity
Arterial distensibility is a measure of the artery’s ability to
expand and contract with cardiac pulsation and relaxation.
Aging, hypertension and other risk factors can alter the
structural and functional properties of the arterial wall,
leading to a decrease in arterial distensibility, which seems
to be a common pathologic mechanism among CV dis-
eases [37]. The aorta is a major vessel of interest when
Figure 1 Example of automatic edge detection of intima-media thickness (IMT) and diameter on B-mode scan of a common carotid
artery (top right). Graph shows changes over cardiac cycles of diameter (top) and IMT (bottom). The panel on bottom left reports mean values
of diameter, IMT and some parameter of carotid stiffness.
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inal aorta makes the largest contribution to the arterial
buffering function [37]. Elastic properties of conduit arter-
ies vary along the arterial tree, with proximal arteries be-
ing more elastic and distal ones stiffer. Aging, along with
blood pressure, is the main determinant of stiffness in
both carotid and aortic stiffness [43,44], inducing a re-
duced synthesis and an increased degradation of elastin,
and on the other hand to an increased synthesis and re-
duced degradation of type 1 and type 3 collagen [45].
Aortic degeneration is responsible for most of the
pathophysiologic effects of central pressure and arterial
stiffness on the left ventricle, brain, and kidney [5,7,37].
The assessment of PWV is considered to be the “gold
standard” measurement of aortic stiffness, as it is a sim-
ple, non-invasive and reproducible method and has the
largest amount of clinical evidence, providing the pre-
dictive value of aortic stiffness for CV events [12].
PWV can be measured from various arterial sites: the
pressure waveforms are usually obtained trans-cutaneously
at the common carotid artery and the femoral artery. The
distance covered by the waves is assimilated to the surface
distance between the two recording sites, and the time
delay (or transit time) measured between the feet of the
two waveforms is estimated. PWV is then calculated as the
ratio of the distance to the time delay: PWV= (distance/
transit time) (Figure 2).Distance has to be measured precisely, since small in-
accuracies may influence the absolute value of PWV
[46]. Inaccurate distance measurements might occur
with abdominal obesity, particularly in men [47]. In the
past decade, different modalities for aortic path estima-
tion have been used, leading to heterogeneous and non-
comparable results among different research groups, but
very recently, accumulation of data using magnetic res-
onance imaging allow the definition of a shared method-
ology in all the laboratories [48].
Transit time is commonly estimated by the foot-to-
foot method (Figure 2). The foot of the wave is defined
at the end of diastole, when the steep rise of the wave
front begins. The transit time is the time of travel of the
foot of the wave over a known distance.
The most accepted methods for cfPWV measurement
are those using mechano-transducers or applanation to-
nometers (Figure 2). Pressure waveforms can be recorded
simultaneously to provide automated measurement of
PWV as with the Complior System (Colson, Les Lilas,
France) which employs dedicated mechano-transducers
directly applied on the skin [49]. The transit time is deter-
mined by means of a correlation algorithm between each
simultaneous recorded wave. Pressure waves can also be
recorded sequentially from different sites by a single high-
fidelity applanation tonometer, and transit time calculated
using registration with a simultaneously recorded ECG,
Figure 2 Figure shows a schematic representation of pulse wave velocity (PWV) according to current international recommendations
[48]. Pulse wave travel time: t; distance: D; CV: cardiovascular.
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Australia) [50]. Brachial-ankle pulse-wave velocity (baPWV)
has been suggested as a simpler alternative to cf-PWV,
since the aortic PWV was the main independent correlate
of baPWV, followed by leg PWV [51]. Finally, the disten-
sion waves obtained at a short time interval at two arterial
sites (common carotid and femoral artery, for instance) by
high-resolution echo-tracking devices can be also used to
calculate PWV, using the R-wave of the ECG for calculating
the time delay [37].
In 2010 the Reference Value for Arterial Stiffness Collab-
oration provided normal and reference values for cfPWV,
calculated using a standardized methodology in a large
European population (data from 16 867 individuals and pa-
tients from 13 different centers across 8 European coun-
tries) [52]. Values were defined in a ‘normal’ population of
individuals having optimal blood pressure values and no
additional CV risk factors, whereas ‘reference’ values were
identified in individuals or patients presenting CV risk fac-
tors. For normal and reference values, the population was
categorized according to age decade and BP category.
As already mentioned, current hypertension guidelines
include cfPWV in the list of factors influencing the
prognosis of hypertensive patients: a threshold cfPWV
value of greater than 10 m/s is considered as an index of
large artery stiffening and an indicator of sub-clinical
organ damage [4]. This value derives from a standard-
ized calculation for PWV, which takes into consideration
the most accurate approximation of the distance be-
tween the carotid and femoral artery [48]. However, it is
still discussed whether this threshold or a series of
threshold values (such as > 90th percentile or > 75th per-
centile of normal values for PWV dependent upon age)
would be more accurate reference values for identifying
people at increased CV risk [53].
Flow-mediated dilation
Endothelium plays a primary role in the control of vas-
cular function and structure, by production and releaseof nitric oxide (NO) under the influence of agonists and
by mechanical forces, such as shear stress [54]. NO not
only cause vasodilation, but also inhibits key mecha-
nisms of vascular damage, such as platelet aggregation,
vascular smooth muscle cell proliferation and migration
and monocyte adhesion [54,55]. Despite its key import-
ance in vascular pathophysiology, NO can be hardly
assayed directly, for its biochemical properties. For this
reason, several indirect methods for assessing stimulated
NO release, and thus endothelial function, have been de-
veloped [9,56,57].
Endothelial function in clinical research is usually tested
by vascular reactivity studies [56], measuring the degree of
vasodilation as the changes in diameter induced by specific
stimuli in the macrocirculation (e.g. in the epicardial or bra-
chial arteries) and the microcirculation (coronary, periph-
eral muscle, subcutaneous and skin microcirculation).
FMD is a non-invasive method, introduced in 1992 [58],
which is based on the measurement of brachial artery
diameter changes after an increase in shear stress induced
by reactive hyperemia (Figure 3). The NO-dependency of
FMD has been documented invasively with intra-arterial
infusion of by NG-mono-methyl-L-arginine (L-NMMA), a
specific inhibitor of NO synthase, which reduced of al-
most 2/3 the dilation of the artery (radial or brachial) in
response to shear stress [59,60].
Available data indicate that impaired FMD is associated
with almost every condition predisposing to atheroscler-
osis and CV disease, as a putative intermediate step for
the development of subclinical target organ damage and
later clinical events. Cross-sectional studies have shown a
correlation between FMD and C-IMT [61,62] and C- IMT
progression over a 6-year follow- up in a population free
of cardiovascular disease [63] or after 1 year, in hyperten-
sive, postmenopausal women [64]. Impaired FMD has
been shown to be an independent predictor of in-stent
stenosis after single-vessel coronary interventions [65]. In
the setting of primary prevention, most of the studies
showed that FMD is predictive of cardiovascular events
Figure 3 Example of automatic edge detection and real-time analysis of B-mode and doppler signal during flow mediated dilation
(FMD) assessment (top right). Graphs show changes in brachial artery diameter diameter (D, top panel) and shear rate (SR, left). The panel on
bottom left reports mean baseline, maximun) values of D and SR, and the computation of FMD.
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patients such as after elective vascular surgery [66], in pa-
tients with chest pain [67], in hypertensive patients [68,69]
and in large population studies [70,71]. A recent meta-
analysis summarized the results of four population-based
cohort studies, and ten cohort studies, involving 5,547
participants, showing a pooled relative risk of cardiovascu-
lar events per 1 % increase in brachial FMD, adjusted for
confounding risk factors of 0.87 (95% CI, 0.83-0.91), which
was consistent among all subgroups evaluated [72]. Ro-
bust evidence on the effect of non- and pharmacological
interventions on endothelial function is available, in par-
ticular with antihypertensive treatments [73]. However,
only two studies suggest that postmenopausal hyperten-
sive women [74] and patients with stable coronary artery
disease [75] not responding to the interventions with an
FMD improvement are at considerable higher risk of fur-
ther events. In a direct comparison of different biomarkers
in a cohort of 1330 intermediate-risk participants of the
MESA study, FMD failed to demonstrate increased dis-
crimination and risk classification in comparison to a
standard approach [27]. However, this negative result does
not put an end to the debate, since FMD reproducibility
in the MESA study was quite low [27] in comparison to
state-of-the art approaches [76,77], stressing even more
the importance of a correct methodology when ap-
proaching this technique.FMD implies the measurement of brachial artery
diameter before inflation (to 200–300 mmHg) and after
release (5 minutes later) of a sphygmomanometer cuff
placed on the forearm [78]. Despite the apparent simpli-
city, its application is technically challenging [8,56,57].
Indeed, some important caveats should be considered,
for the effect of environmental or physiological influ-
ences [79] and technical variability of its measurement,
which requires standardization [8,78,80].
Variations in the technique, such as the position of the
occluding cuff at the arm instead of the forearm may pro-
duce heterogeneous results that are less representative of
local NO activity [8,57], although possibly with the same
prognostic significance [81]
The application of a rigorous methodology is able to re-
duce FMD variability in single center [82] and multicenter
studies [76,77]. This comprises certified operator training
[78] and defined experimental settings, including adjust-
able stereotactic probe-holding device and automated
computer-assisted brachial artery measurements [83,84],
that should be implemented in all FMD laboratories. In
particular, automated real-time systems for diameter
measurement are able to enhance reliability of FMD (Fig-
ure 3), by reducing the number of rejected examinations
due to poor quality and/or instability of the images [76,85]
and improving operator’s learning curve during training
and certification [86].
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20 years ago, it is still evolving in terms of study protocol,
variables considered and mathematical analysis. Alterna-
tive computation of FMD, independent of diameter, has
been recently suggested [87], since the larger is the diam-
eter, the smaller are the relative percent changes [80]. The
issue of the assessment of endothelial function not only in
the hyperemic state has been also introduced by measur-
ing vasoconstriction during cuff inflation (low-flow–medi-
ated constriction, FMC) particularly at the level of the
radial artery [88]. Another important aspect that is gaining
growing attention is the acquisition of stimulus for FMD
itself, such as the reactive hyperemic flow, and the in-
duced shear stress, which might be an important measure
of peripheral microvascular function [80,89,90]. Finally,
the evaluation of endothelium-independent dilator re-
sponse should be always tested by the administration of
low-dose sublingual nitroglycerine [91], to exclude the
possibility that altered smooth muscle cell contractility
may influence the endothelium-dependent response. Fur-
thermore, the evaluation of smooth muscle cell function
as part of the FMD protocol might also convey additional
information about vascular health in patients with CV risk
factors and disease [92].
Conclusions
Prevention of CV disease requires risk stratification and
treatment of classical risk factors, such as smoking, hyper-
tension hypercholesterolemia and diabetes. Nevertheless,
classic risk stratification might be not sufficient to provide
an accurate estimate of probability of future CV events.
Vascular biomarkers, which are parameters of subclin-
ical cardiovascular disease, could increase the estimation
of the individual cardiovascular risk and improve strat-
egies for effective prevention.
Several vascular markers obtained by ultrasound and
other non-invasive techniques have been proposed for this
aim. Greater evidence is available for increased C-IMT
and cf-PWV, which are able to improve risk reclassifica-
tion and can be used to identify subclinical target organ
damage. FMD only recently has reached an adequate level
of methodological standardization to be proposed as sur-
rogate endpoint in clinical trials. A solid methodology will
allow to verify the intriguing hypothesis that assessment
of changes in vascular biomarkers after therapy might re-
late to the development subclinical target organ damage
or events in future clinical trials.
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